Products
Products
All Photos(1)
Y0001533
Praziquantel for system suitability
European Pharmacopoeia (EP) Reference Standard
All Photos(1)
Synonym(s):
2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one, Praziquantel
Empirical Formula (Hill Notation):
C19H24N2O2
CAS Number:
Molecular Weight:
312.41
Beilstein:
761557
MDL number:
PubChem Substance ID:
NACRES:
NA.24
grade
pharmaceutical primary standard
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
O=C1CN(CC2N1CCc3ccccc23)C(=O)C4CCCCC4
InChI
1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2
InChI key
FSVJFNAIGNNGKK-UHFFFAOYSA-N
Looking for similar products? Visit Product Comparison Guide
Related Categories
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Packaging
Unit quantity: 10 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Caution
Please find SDS provided by EDQM here..
Other Notes
Sales restrictions may apply.
Certificate of Analysis
Enter Lot Number to search for Certificate of Analysis (COA).
Certificate of Origin
Enter Lot Number to search for Certificate of Origin (COO).
More Documents
Quotes and Ordering
J M Bygott et al.
Acta tropica, 111(2), 95-101 (2009-04-21)
The role of praziquantel in hydatid disease has not been well defined. This review evaluates the evidence on the use of praziquantel in treatment of cystic hydatid disease from in vitro and in vivo animal studies, human clinical studies and
Charles H King et al.
PLoS neglected tropical diseases, 5(9), e1321-e1321 (2011-09-29)
Controversy persists about the optimal approach to drug-based control of schistosomiasis in high-risk communities. In a systematic review of published studies, we examined evidence for incremental benefits from repeated praziquantel dosing, given 2 to 8 weeks after an initial dose
M J Doenhoff et al.
Parasitology, 136(13), 1825-1835 (2009-03-14)
Treatment with praziquantel (PZQ) has become virtually the sole basis of schistosomiasis control in sub-Saharan Africa and elsewhere, and the drug is reviewed here in the context of the increasing rate that it is being used for this purpose. Attention
Wei Wang et al.
Parasitology research, 111(5), 1871-1877 (2012-10-12)
Since praziquantel was developed in 1970s, it has replaced other antischistosomal drugs to become the only drug of choice for treatment of human schistosomiases, due to high efficacy, excellent tolerability, few and transient side effects, simple administration, and competitive cost.
Wei Wu et al.
Parasitology research, 112(3), 909-915 (2013-01-30)
Schistosomiasis remains a major public health problem with an estimated 200 million people infected in the world, and in China, schistosomiasis japonica is endemic in the south part of the country. In 1960s, before praziquantel was developed, there were about
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service